Inhibrx Biosciences, Inc. (INBX)

US — Healthcare Sector
Peers: NKTR  SNDX  RLAY  AMLX  ELVN  ORIC  IMTX  ATAI  SANA  CVAC 

Automate Your Wheel Strategy on INBX

With Tiblio's Option Bot, you can configure your own wheel strategy including INBX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol INBX
  • Rev/Share 0.0905
  • Book/Share 2.3795
  • PB 34.5576
  • Debt/Equity 0.1897
  • CurrentRatio 4.4861
  • ROIC -1.0716

 

  • MktCap 1195931576.0
  • FreeCF/Share -9.2673
  • PFCF -8.3376
  • PE -8.2068
  • Debt/Assets 0.0394
  • DivYield 0
  • ROE -1.8606

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Inhibrx: Ozekibart Beyond Chondrosarcoma, With Other Targeted Indications, Too
INBX
Published: January 13, 2026 by: Seeking Alpha
Sentiment: Positive

Inhibrx Biosciences, Inc. remains a Strong Buy, driven by multiple near-term catalysts, notably the Q2 2026 BLA filing for ozekibart in chondrosarcoma. INBX expects to release pivotal progression-free survival [PFS] data for ozekibart + FOLFIRI in heavily pretreated metastatic colorectal cancer in 2026. Ozekibart is also advancing in Ewing Sarcoma, with enrollment completion expected Q2 2026 and potential FDA meeting for accelerated approval in H2 2026.

Read More
image for news Inhibrx: Ozekibart Beyond Chondrosarcoma, With Other Targeted Indications, Too
Inhibrx: Positive Ozekibart Data For Bone Cancer Leads To Q2 2026 BLA Filing
INBX
Published: October 24, 2025 by: Seeking Alpha
Sentiment: Positive

Inhibrx Biosciences, Inc. delivered strong phase 2 results for ozekibart (INBRX-109) in advanced chondrosarcoma, doubling progression-free survival over placebo. INBX plans to file a Biologics License Application for ozekibart in chondrosarcoma by Q2 2026, with expansion opportunities in colorectal cancer and Ewing sarcoma showing promise. Additional catalysts for INBX stock include upcoming data for INBRX-106, a hexavalent OX40 agonist, targeting HNSCC and NSCLC, expected in Q4 2025.

Read More
image for news Inhibrx: Positive Ozekibart Data For Bone Cancer Leads To Q2 2026 BLA Filing

About Inhibrx Biosciences, Inc. (INBX)

  • IPO Date 2024-06-04
  • Website https://inhibrx.com
  • Industry Biotechnology
  • CEO Mark Paul Lappe
  • Employees 156
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.